InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...
InflaRx N.V. (NASDAQ: IFRX) opened Friday in the red. The German-based biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced that it will ...
As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential ...
Regeneron rebounds from regulatory and clinical setbacks as Dupixent and pipeline catalysts fuel growth. Click here to read ...
Kodiak Sciences Inc. , a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced it will present ...
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient popu ...
Kyverna Therapeutics reported robust early Phase 2 miv-cel data in gMG, showing 100% response rates and deep, durable ...
SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...
CLEVELAND, Ohio — The benefits of getting regular exercise, combining two cancer drugs with chemotherapy, and using AI to ...
First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025Dupixent- global net sales (recorded by Sanofi) increased 33% to $4.9 billion EYLEA HD- U.S. net sales increased 52% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results